Discontinued

London/Sodertalje—AstraZeneca’s decision to drop Viozan (AR-C68397AA) for chronic obstructive pulmonary disease (COPD) could be GlaxoSmithKline’s gain.

Related Content:

Pharmaceutical Executive-08-01-2001

Biotech Hotbed

Decision Making at Digital Speed

Mergers: Big Pharma Shrinks Some